CN112888673B - 新颖mct4抑制剂及其用途 - Google Patents

新颖mct4抑制剂及其用途 Download PDF

Info

Publication number
CN112888673B
CN112888673B CN201980035699.6A CN201980035699A CN112888673B CN 112888673 B CN112888673 B CN 112888673B CN 201980035699 A CN201980035699 A CN 201980035699A CN 112888673 B CN112888673 B CN 112888673B
Authority
CN
China
Prior art keywords
mct4
cancer
subject
cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980035699.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112888673A (zh
Inventor
吴勇
杰伊·瓦德加玛
黄志敏
吴珂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charles Drew University Of Medical Sciences
Original Assignee
Charles Drew University Of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Drew University Of Medical Sciences filed Critical Charles Drew University Of Medical Sciences
Publication of CN112888673A publication Critical patent/CN112888673A/zh
Application granted granted Critical
Publication of CN112888673B publication Critical patent/CN112888673B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980035699.6A 2018-04-25 2019-04-25 新颖mct4抑制剂及其用途 Active CN112888673B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662637P 2018-04-25 2018-04-25
US62/662,637 2018-04-25
PCT/US2019/029192 WO2020033019A2 (en) 2018-04-25 2019-04-25 Novel mct4 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN112888673A CN112888673A (zh) 2021-06-01
CN112888673B true CN112888673B (zh) 2022-07-29

Family

ID=68532786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035699.6A Active CN112888673B (zh) 2018-04-25 2019-04-25 新颖mct4抑制剂及其用途

Country Status (7)

Country Link
US (1) US10919878B2 (OSRAM)
EP (1) EP3784650B1 (OSRAM)
JP (1) JP7115671B2 (OSRAM)
CN (1) CN112888673B (OSRAM)
AU (1) AU2019317518B2 (OSRAM)
CA (1) CA3098189C (OSRAM)
WO (1) WO2020033019A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544375B2 (en) * 2019-09-05 2026-02-10 The Board Of Trustees Of The Leland Junior University Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
US20240270749A1 (en) 2021-05-21 2024-08-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291917A (zh) * 2003-11-28 2008-10-22 诺瓦提斯公司 治疗蛋白激酶依赖性疾病的二芳基脲衍生物
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
CN107635404A (zh) * 2015-06-12 2018-01-26 威特瑞有限公司 用于治疗疾病的mct4抑制剂
CN108368060A (zh) * 2017-12-21 2018-08-03 中国科学院合肥物质科学研究院 一类新型的嘧啶类衍生物激酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226438A (OSRAM) 1968-12-03 1971-03-31
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2014189152A1 (en) 2013-05-24 2014-11-27 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
WO2016118822A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Chromenone inhibitors of monocarboxylate transporters
WO2016118823A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291917A (zh) * 2003-11-28 2008-10-22 诺瓦提斯公司 治疗蛋白激酶依赖性疾病的二芳基脲衍生物
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
CN107635404A (zh) * 2015-06-12 2018-01-26 威特瑞有限公司 用于治疗疾病的mct4抑制剂
CN108368060A (zh) * 2017-12-21 2018-08-03 中国科学院合肥物质科学研究院 一类新型的嘧啶类衍生物激酶抑制剂

Also Published As

Publication number Publication date
AU2019317518A1 (en) 2020-12-17
CA3098189A1 (en) 2020-02-13
AU2019317518B2 (en) 2023-05-25
EP3784650A4 (en) 2022-01-26
EP3784650B1 (en) 2023-09-06
WO2020033019A2 (en) 2020-02-13
CN112888673A (zh) 2021-06-01
CA3098189C (en) 2025-05-13
US20190352282A1 (en) 2019-11-21
WO2020033019A3 (en) 2020-04-02
US10919878B2 (en) 2021-02-16
JP7115671B2 (ja) 2022-08-09
EP3784650C0 (en) 2023-09-06
JP2021522345A (ja) 2021-08-30
EP3784650A2 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
JP7115671B2 (ja) 新規なｍｃｔ４阻害剤及びその使用
JP6294889B2 (ja) ウイルス疾患の処置におけるｍｅｋ阻害物質
US11446353B2 (en) Compositions and methods for the treatment of fungal infections
US20220280450A1 (en) Prevention and treatment of coronavirus and related respiratory infections
US20240197743A1 (en) Wee1 compound for treating uterine serous carcinoma
Xia et al. Artesunate alleviates 5-fluorouracil-induced intestinal damage by suppressing cellular senescence and enhances its antitumor activity
Jhun et al. Vitamin D attenuates pain and cartilage destruction in OA animals via enhancing autophagic flux and attenuating inflammatory cell death
Song et al. The MEK1/2 inhibitor AZD6244 sensitizes BRAF-mutant thyroid cancer to vemurafenib
Liu et al. Gamabufotalin induces apoptosis and cytoprotective autophagy through the mTOR signaling pathway in hepatocellular carcinoma
CN101389334A (zh) 埃坡霉素d的给药方法
CN106692150B (zh) 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
WO2021032212A1 (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/a及其应用
US20230381119A1 (en) Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
Hu et al. Lupiwighteone as an antitumor agent reverses multidrug resistance in K562/ADR cells by regulating cellular prion protein-Oct4 axis
CN121243179B (zh) 盐酸帕唑帕尼在制备卵巢功能保护药物方面的应用
TWI924837B (zh) 用於治療子宮漿液性癌之ｗｅｅ１化合物
US20240033238A1 (en) Combination of compounds for use in therapy
CN100455289C (zh) 孟德拉明类抗癌药
Ikematsu How to use anti-influenza drugs: laninamivir octanoate
CN117500505A (zh) 用于治疗子宫浆液性癌的wee1化合物
TW202606659A (zh) Ｋｉｆ１８ａ抑制劑治療結直腸癌的用途
Xu et al. Quinacrine Inhibits Hepatocellular Carcinoma Growth and Enhances the Anti-HCC Effects of Lenvatinib
WO2026002202A1 (zh) Kif18a抑制剂治疗非小细胞肺癌的用途
CN117357528A (zh) 一种激酶抑制剂的新用途
Baulies et al. Lysosomal Cholesterol Accumulation Sensitizes To Acetaminophen Hepatotoxicity By Impairing Mitophagy: 51

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant